| Scrip Code | 542650 |
|---|---|
| NSE Symbol | METROPOLIS |
| MSEI Symbol | NOTLISTED |
| ISIN | INE112L01020 |
| Name of company | Metropolis Healthcare Limited |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2025 |
| Date of end of financial year | 31-03-2026 |
| Date of board meeting when results were approved | 04-02-2026 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 30-01-2026 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Type | Quarterly |
| Reporting Quarter | Third quarter |
| Nature of report standalone or consolidated | Consolidated |
| Whether results are audited or unaudited for the quarter ended | Unaudited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | Unaudited |
| Segment Reporting | Single segment |
| Description of single segment | Pathology Services |
| Start date and time of board meeting | 04-02-2026 11:15:00 |
| End date and time of board meeting | 04-02-2026 15:40:00 |
| Whether cash flow statement is applicable on company | |
| Type of cash flow statement | |
| Declaration of unmodified opinion or statement on impact of audit qualification | Not applicable |
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-10-2025 | 01-04-2025 |
| B | Date of end of reporting period | 31-12-2025 | 31-12-2025 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Consolidated | Consolidated |
| 1 | Income | ||
| Revenue from operations | 40,590.97 | 1,22,116.43 | |
| Other income | 901.55 | 1,742.29 | |
| Total income | 41,492.52 | 1,23,858.72 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 7,923.70 | 24,603.48 |
| (b) | Purchases of stock-in-trade | 0.00 | 0.00 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | 0.00 | 0.00 |
| (d) | Employee benefit expense | 9,422.49 | 28,189.74 |
| (e) | Finance costs | 573.05 | 1,661.09 |
| (f) | Depreciation, depletion and amortisation expense | 3,187.83 | 9,513.11 |
| (f) | Other Expenses | ||
| 1 | Laboratory testing charges | 805.73 | 1,869.83 |
| 2 | Other expenses | 12,954.38 | 38,170.52 |
| Total other expenses | 13,760.11 | 40,040.35 | |
| Total expenses | 34,867.18 | 1,04,007.77 | |
| 3 | Total profit before exceptional items and tax | 6,625.34 | 19,850.95 |
| 4 | Exceptional items | (909.65) | (909.65) |
| 5 | Total profit before tax | 5,715.69 | 18,941.30 |
| 6 | Tax expense | ||
| 7 | Current tax | 1,334.18 | 5,121.76 |
| 8 | Deferred tax | 172.80 | (202.71) |
| 9 | Total tax expenses | 1,506.98 | 4,919.05 |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 |
| 11 | Net Profit Loss for the period from continuing operations | 4,208.71 | 14,022.25 |
| 12 | Profit (loss) from discontinued operations before tax | 0.00 | 0.00 |
| 13 | Tax expense of discontinued operations | 0.00 | 0.00 |
| 14 | Net profit (loss) from discontinued operation after tax | 0.00 | 0.00 |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0.00 | 0.00 |
| 16 | Total profit (loss) for period | 4,208.71 | 14,022.25 |
| 17 | Other comprehensive income net of taxes | 164.87 | 146.57 |
| 18 | Total Comprehensive Income for the period | 4,373.58 | 14,168.82 |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | 4,138.562 | 13,911.446 | |
| Total profit or loss, attributable to non-controlling interests | 70.152 | 110.804 | |
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | 4,303.157 | 14,058.473 | |
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | 70.417 | 110.346 | |
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 1,036.45 | 1,036.45 | |
| Face value of equity share capital | 2 | 2 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | ||
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 7.99 | 26.85 | |
| Diluted earnings (loss) per share from continuing operations | 7.94 | 26.69 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | 0 | |
| Diluted earnings (loss) per share from discontinued operations | 0 | 0 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 7.99 | 26.85 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | 7.94 | 26.69 | |
| 24 | Debt equity ratio | ||
| 25 | Debt service coverage ratio | ||
| 26 | Interest service coverage ratio | ||
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
| Textual Information(1) | Refer the financial results pdf uploaded on stock exchange for the full notes |
|---|
| Debt equity ratio | |
|---|---|
| Debt service coverage ratio | |
| Interest service coverage ratio |
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|---|
| Date of start of reporting period | 01-10-2025 | 01-04-2025 | |||||
| Date of end of reporting period | 31-12-2025 | 31-12-2025 | |||||
| Whether results are audited or unaudited | Unaudited | Unaudited | |||||
| Nature of report standalone or consolidated | Consolidated | Consolidated | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| Total Segment Revenue | |||||||
| Less: Inter segment revenue | |||||||
| Revenue from operations | |||||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| Total Profit before tax | |||||||
| i. Finance cost | |||||||
| ii. Other Unallocable Expenditure net off Unallocable income | |||||||
| Profit before tax | |||||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| Total Segment Asset | |||||||
| Un-allocable Assets | null | null | |||||
| Net Segment Asset | null | null | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| Total Segment Liabilities | |||||||
| Un-allocable Liabilities | null | null | |||||
| Net Segment Liabilities | null | null | |||||
| Disclosure of notes on segments | |||||||
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-10-2025 | 01-04-2025 |
| B | Date of end of reporting period | 31-12-2025 | 31-12-2025 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Consolidated | Consolidated |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| Total Amount of items that will not be reclassified to profit and loss | |||
| 2 | Income tax relating to items that will not be reclassified to profit or loss | (228.56) | (3.81) |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| Total Amount of items that will be reclassified to profit and loss | |||
| 4 | Income tax relating to items that will be reclassified to profit or loss | 63.69 | (142.76) |
| 5 | Total Other comprehensive income | 164.87 | 146.57 |